Pemvidutide
In a trial with 64 people, the 1.8 mg pemvidutide group lost an average 6.2% of body weight after 24 weeks (PMID 41113119, NCT05292911; checked 25 Aug 2026). The placebo group lost an average 1.4% (PMID 41113119; checked 25 Aug 2026). The 95% ranges were -8.4% to -3.9% and -3.5% to 0.7% (PMID 41113119; checked 25 Aug 2026). Altimmune paid for the trial. Its staff helped plan the study, collect the data, assess the results, and write the paper.
What is pemvidutide?
Pemvidutide is a peptide drug that acts at the GLP-1 and glucagon receptors (PMID 41113119; checked 25 Aug 2026). The United States GSRS lists it as a protein with one subunit under UNII A35F525WBG and CAS 2538014-94-5. These facts were checked 25 Aug 2026.
No clear alias is listed.
Why does the code ALT-801 need care?
Altimmune trial records NCT05006885 and NCT05292911 use ALT-801 for the drug. The United States GSRS gives the exact name ALT-801 to a different protein under UNII QWZ40O5W6K. The two UNIIs were checked 25 Aug 2026.
Six cancer trials also use ALT-801: NCT00496860, NCT01029873, NCT01326871, NCT01478074, NCT01625260, and NCT01670994. Altor BioScience ran those trials. They tested a different fusion protein for cancer. This page does not treat ALT-801 as a clear alias for the drug.
What did the human trial measure?
The paper reports a 24-week follow-up to a randomised, double-blind, placebo-controlled MASLD trial (PMID 41113119, NCT05292911; checked 25 Aug 2026). Sixty-four adults joined the follow-up (PMID 41113119; checked 25 Aug 2026). Some had type 2 diabetes. Others did not.
In the 1.8 mg group, the estimated liver fat change was -75.2% (95% CI -93.8 to -56.7) (PMID 41113119; checked 25 Aug 2026). For placebo, it was -14.0% (95% CI -32.2 to 4.3) (PMID 41113119; checked 25 Aug 2026). The test gave p < 0.001 (PMID 41113119; checked 25 Aug 2026).
Altimmune paid for the trial. Authors who worked at the firm helped plan the study and collect the data. They also assessed the results and wrote the paper. Eight authors said they worked for Altimmune and held a financial stake in it (PMID 41113119; checked 25 Aug 2026).
What else did the trial record?
Nausea affected 33.3% of people who got the drug in the follow-up (PMID 41113119; checked 25 Aug 2026). Most cases were mild or moderate. Two of 16 people in one group stopped due to side effects (PMID 41113119; checked 25 Aug 2026). One of 15 people in another group stopped for the same reason (PMID 41113119; checked 25 Aug 2026). No one in the 14-person high group stopped due to a side effect (PMID 41113119; checked 25 Aug 2026).
The paper found no serious side effects in the drug groups. It listed two severe events that the study team judged unrelated to the drug (PMID 41113119; checked 25 Aug 2026). Mild or moderate diarrhoea and constipation were also seen. They went away without care.
Just 64 of the 94 people from the first trial joined the follow-up (PMID 41113119; checked 25 Aug 2026). The trial left out people with more severe liver inflammation and fibrosis. The authors say this limits how well the results apply to people with more advanced MASH.
How much human research is registered?
Name and code searches in ClinicalTrials.gov found nine trials run by Altimmune on 25 Aug 2026. Five are phase 1: NCT04561245, NCT04972396, NCT05006885, NCT05134662, and NCT05292911. Four are phase 2: NCT05295875, NCT05989711, NCT06987513, and NCT07009860.
Each named trial record had no results posted on 25 Aug 2026. Some trial results are in papers, such as PMID 41113119. Evidence tier B shows that human trials exist. It does not prove approval.
The EudraCT pages gave no count we could read. Their count stays unclear, not zero.
What is pemvidutide's regulatory status?
EU status: unclear. The name was not in the EMA central medicines list checked 25 Aug 2026. The list does not cover every national approval in an EU state.
When was pemvidutide first documented?
No sound month is known for when the drug first circulated. The earliest linked paper in the set is from 2022 (PMID 35461369; checked 25 Aug 2026). A paper year and a trial entry do not show when the drug first appeared outside studies. This limit was checked 25 Aug 2026.
What do users report?
No full first-person thread about the drug was found in the forum archive we could read. No forum quote or group claim is included.
→ What can be inside a grey-market vial → All compounds in the register